EFFECT OF ORMELOXIFENE (CENTCHROMAN) ON MASTALGIA AND MULTIPLE FIBROADENOMA

Abstract

Introduction: Both mastalgia and fibroadenomas are the most prevalent benign breast disorders that present in breast clinics, and both create a great deal of concern in their patients. Hormonal medication treatments, among other forms of treatment, are becoming more and more common. An antiestrogenic medication called ormeloxifene (centchroman) has been demonstrated to lessen fibroadenoma size and to lessen discomfort in people with mastalgia.

Objectives: Ormeloxifene is a nonsteroidal medication that selectively inhibits estrogen. Because of its distinctive antiestrogen activity, it can be used to treat many tiny fibroadenomas and mastalgia. This study aimed to assess the effects of ormeloxifene (centchroman) and mastalgia on multiple fibroadenomas.

Materials and Methods: Among them were patients with benign breast disease who visited our outpatient surgery department between May 2023 and December 2023. For three months, they received Ormeloxifene 30 mg on alternate days, and they underwent follow-up care for six months. The Visual Analog Scale (VAS) for pain and ultrasonography (USG) for breast lump size were among the parameters that were recorded.

Results: The investigation involved sixty patients. Thirty patients were administered Ormeloxifene and thirty patients were administered other drugs. In mastalgia, we had a very good response; 90% of patients had a reduction in VAS scores from 7 to 3 within the first week, and nearly all were pain-free after a month. According to the final result, patients who received ormeloxifene had completely resolved the lump in 3.33% of cases by the end of three months and 30% by the end of six months. Partial or no response was found in 20% of the patients by 3rd month and 46.67% of the patients who were administered Ormeloxifene.

Conclusion: For the treatment of fibroadenoma and mastalgia, ormeloxifene has been shown to be a safe medication. In the group with mastalgia, its findings were very noteworthy. After six months, there had been fewer procedures and a significant increase in patient satisfaction.